Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHYOX3 long-term rollover study of DCR-PHXC in primary hyperoxaluria
jRCT2041200091Active, not recruiting
- Sponsor
- Dicerna Pharmaceuticals, Inc.
- Start
- Jan 2021
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Open-label, single-arm trial of nedosiran in Primary hyperoxaluria (PH), sponsored by Dicerna Pharmaceuticals, Inc. Primary endpoint: Annual rate of decline in eGFR in participants with PH1. Started Jan 2021; status: active, not recruiting.
02
Drugs
nedosiran
03
Conditions
Primary hyperoxaluria (PH)
Beyond the preview
Go deeper on jRCT2041200091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041200091.